2. Search Result
Search Result
Results for "

allograft rejection

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

6

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103193
    NKH477

    Colforsin dapropate hydrochloride

    		 Adenylate Cyclase Cardiovascular Disease
    NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477
  • HY-B0199A
    Mycophenolate mofetil hydrochloride
    10+ Cited Publications

    RS 61443 hydrochloride; TM-MMF hydrochloride

    		 Interleukin Related Inflammation/Immunology
    Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate mofetil hydrochloride
  • HY-110217
    BMS-566419

    		IMPDH Inflammation/Immunology
    BMS-566419 is an orally active IMPDH inhibitor with an IC50 of 91 nM against human IMPDH I and 68 nM against human IMPDH II. BMS-566419 exerts anti-heart transplant rejection and anti-renal fibrosis effects, and inhibits the expression of MCP-1, TGF-β1 as well as antibody production. BMS-566419 can be used in research on renal fibrosis and organ transplantation .
    BMS-566419
  • HY-P990667
    STX-100

    		Integrin TGF-beta/Smad Inflammation/Immunology Cancer
    STX-100 is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
    STX-100
  • HY-B0199S
    Mycophenolate Mofetil-d4

    		Isotope-Labeled Compounds Interleukin Related Cancer
    Mycophenolate Mofetil-d4 is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil-d4
  • HY-P991279
    Mik-Beta-1

    		Interleukin Related Inflammation/Immunology
    Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
    Mik-Beta-1
  • HY-B0199R
    Mycophenolate Mofetil (Standard)

    RS 61443 (Standard); TM-MMF (Standard)

    		 Reference Standards Interleukin Related Cancer
    Mycophenolate Mofetil (Standard) is the analytical standard of Mycophenolate Mofetil. This product is intended for research and analytical applications. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil (Standard)
  • HY-P991543
    BTI-322

    		CD2 Inflammation/Immunology Cancer
    BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
    BTI-322
  • HY-B0199AS
    Mycophenolate Mofetil-d4 hydrochloride

    RS 61443-d4 hydrochloride; TM-MMF-d4 hydrochloride

    		 Isotope-Labeled Compounds Interleukin Related Cancer
    Mycophenolate Mofetil-d4 hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil-d4 hydrochloride
  • HY-114602
    AR-C117977

    		Monocarboxylate Transporter Inflammation/Immunology
    AR-C117977 is a potent monocarboxylate transporter (MCT1) inhibitor. AR-C117977 prolongs the survival of skin and heart sllograft. AR-C117977 inhibits the development of transplant arteriosclerosis in aortic allografts partially, but was unable to inhibit alloantibody production after transplantation. AR-C117977 shows potent immunosuppressive properties in vivo effectively preventing acute but not chronic allograft rejection in the mouse .
    AR-C117977
  • HY-123625
    R-348 choline

    R-932348 choline

    		 Interleukin Related JAK Syk Inflammation/Immunology
    R-348 (R-932348) choline is a potent and orally active JAK3 and Syk inhibitor. R-348 reduces IFN-γ, IL-6, and IL-10 expression. R-348 effectively diminishes acute cardiac allograft rejection .
    R-348 choline
  • HY-123187
    AS2553627

    		JAK Cardiovascular Disease
    AS2553627 is a type of JAK inhibitor, with IC50 values of 0.46, 0.30, 0.14, and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. AS2553627 can inhibit the proliferation of human and rat T cells stimulated by IL-2, with IC50 values of 2.4 and 4.3 nM, respectively. AS2553627 can reduce cardiac allograft vasculopathy and fibrosis in a rat heart transplant model, effectively extending survival rates. AS2553627 can be used to prevent acute and chronic rejection in heart transplants .
    AS2553627
  • HY-P991921
    TNX-1500

    		TNF Receptor Fc Receptor (FcR) Cardiovascular Disease Endocrinology
    TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1] [2].
    TNX-1500
  • HY-W989139
    Perforin-IN-3

    		Apoptosis Inflammation/Immunology Cancer
    Perforin-IN-3 is a specific perforin inhibitor that blocks perforin-mediated lytic pore formation and subsequent cell lysis. Perforin-IN-3 potently inhibits the killing effect of NK cells on target cells such as leukemia cells, without interfering with FasL- or TRAIL-mediated cell death pathways. Perforin-IN-3 has no effect on pneumolysin and can be used to study autoimmune diseases, allograft rejection, graft-versus-host disease, and familial hemophagocytic lymphohistiocytosis .
    Perforin-IN-3
  • HY-183074
    RO8323

    		CDK Interleukin Related Inflammation/Immunology
    RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC50 of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatory T cell differentiation, inhibits effector T cell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis .
    RO8323
  • HY-103193R
    NKH477 (Standard)

    Colforsin dapropate hydrochloride (Standard)

    		 Reference Standards Adenylate Cyclase Cardiovascular Disease
    NKH477 (Standard) is the analytical standard of NKH477 (HY-103193). This product is intended for research and analytical applications. NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477 (Standard)
  • HY-P992063
    Anti-Mouse CD8α Antibody (YTS 105.18)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody. Anti-Mouse CD8α Antibody (YTS 105.18) binds to CD8α (epitope c) on mouse CD8 + T cells; when used in combination with a non-depleting anti-CD4 antibody, it does not deplete CD8 + T cells but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used in studies of graft rejection .
    Anti-Mouse CD8α Antibody (YTS 105.18)
  • HY-P991749
    Anti-Rat CD25 Antibody (OX-39)

    		Interleukin Related Inflammation/Immunology
    Anti-Rat CD25 Antibody (OX-39) recognizes the 55 kDa low-affinity interleukin-2 receptor α chain (IL-2R α, CD25). Anti-Rat CD25 Antibody (OX-39) interacts with a single class of sites on the alpha chain of the rat R-IL2 with a high affinity (Kd of 0.8 nM) and competes with IL2 binding on this chain (Ki of 0.53 nM). Anti-Rat CD25 Antibody (OX-39) is a weak inhibitor in vitro on IL2-induced proliferation and in vivo on allograft rejection. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-Rat CD25 Antibody (OX-39)
  • HY-117638
    CB 966

    		Drug Derivative Inflammation/Immunology
    CB 966 a Vitamin D3 (HY-15398) analogue, is an immunosuppressant. CB 966 delays rejection of allogeneic skin grafts in mice. CB 966 moderately increases serum calcium levels. CB 966 can be used for the research of allogeneic skin graft rejection .
    CB 966

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: